NOVEL T REGULATORY CELL THERAPY
AUTOIMMUNE DISEASE, TRANSPLANTATION
The ultimate goal of the research in the field of transplantation is to develop immunological tolerance. It would allowed patient body to accept transplanted organ or cells without need to take anymore toxic anti-rejection medications.
We have spent last several years developing conditions for a novel cell therapy, which may ultimately lead to the immunologic tolerance and replace need for immunosuppression.
T-regulatory cells (Tregs) are known to have immunomodulatory properties and can prevent immunologic rejection as well as control autoimmune disease.
In order to utilize Tregs in the clinical setting, we optimized a Tregs ex vivo expansion protocol and conducted a full-scale clinical grade Treg expansion in our cGMP facility at The University of Chicago.
Our subsequent goal is to conduct a phase 1/2 clinical study testing safety and efficacy of the approach in the context of kidney, liver or islet transplantation.
Independently, the same Tregs can apply in many autoimmune diseases bringing hope for full recovery in patients with new onset of type 1 diabetes, multiple sclerosis, Crohn disease, ulcerative colitis, rheumatoid arthritis and primary sclerosing cholangitis.
This cutting edge complex technology is advanced to the level of clinical application and , developed only in a few centers all over the world besides University of Chicago.
We have also established close collaborations with those centers promoting the progress in the field.
Dr. Witkowski is seeking funding for the first phase 1/2 clinical studies allowing to implement this cutting edge technology.
Cost of a single Treg cell processing is $100,000. So, the cost of the study for 10 patients is $1M.